Description

Ksalol 1 mg (Alprazolam) Tablets

Ksalol 1 mg (commonly referenced as Kaslol) is an oral pharmaceutical formulation containing alprazolam, a high-potency, short- to intermediate-acting triazolobenzodiazepine. It functions as a positive allosteric modulator at $\text{GABA}_A$ receptor complexes in the central nervous system. By facilitating the binding of gamma-aminobutyric acid ($\text{GABA}$), it amplifies chloride channel opening, inducing rapid neuronal hyperpolarization and delivering potent anxiolytic, anti-panic, sedative, and muscle-relaxant properties.

Product Overview

Primary Indications

Ksalol 1 mg is prescribed under strict medical supervision for:

• Panic Disorder: Treatment of panic disorder, with or without agoraphobia, characterized by recurrent, unexpected panic attacks and acute anticipatory dread.

• Generalized Anxiety Disorder (GAD): Short-term management of moderate to severe generalized anxiety, somatic tension, and severe situational distress.

• Anxiety Associated with Depression: Short-term adjunctive relief of severe anxiety symptoms co-occurring with depressive mood states.

Key Information & Precautions

• High-Potency Strength: 1 mg of alprazolam is considered a potent single dose (roughly bioequivalent to 10 mg to 20 mg of diazepam). Clinical therapy typically begins at lower doses (0.25 mg to 0.5 mg two to three times daily), with 1 mg tablets generally reserved for titrated, established regimens.

• Dependence, Tolerance, and Abuse Risk: Because of its rapid absorption and pronounced receptor affinity, alprazolam carries a substantial risk of physiological dependence, psychological tolerance, and substance misuse. Courses of treatment should be kept to the shortest possible duration (generally 2 to 4 weeks).

• Severe Withdrawal Hazard: Abrupt cessation or rapid dose reduction can trigger severe, life-threatening withdrawal phenomena, including status epilepticus, delirium, psychosis, autonomic instability, and rebound panic. Any discontinuation requires a gradual, physician-guided tapering protocol.

• Boxed Warning — Concomitant Depressants: Simultaneous use with opioids, alcohol, or other sedative-hypnotics drastically magnifies the risk of profound sedation, life-threatening respiratory depression, coma, and fatal overdose.

• Drug Interactions (CYP3A4): Alprazolam clearance depends heavily on the CYP3A4 pathway. Potent CYP3A4 inhibitors (such as ketoconazole, itraconazole, and clarithromycin) can substantially elevate alprazolam blood concentrations, increasing the hazard of acute toxicity.

• Psychomotor Impairment: Induces somnolence, lightheadedness, ataxia, and delayed reaction time. Patients must avoid driving, operating machinery, or performing safety-critical tasks while under therapy.